MAIA Biotech gets USAN approval for 'ateganosine' as generic name for THIO in NSCLC

MAIA Biotechnology, Inc.

USAN Council approved nonproprietary name 'ateganosine' for lead molecule THIO, a telomere-targeting anticancer agent.
Naming is an essential step in FDA approval process for THIO in advanced non-small cell lung cancer (NSCLC).
MAIA will retain THIO name for clinical trial designations (THIO-101, THIO-102, THIO-103, THIO-104).
No financial terms disclosed; no change in guidance or operations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.